TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.Toni K. Choueiri, Robert J. Motzer, Hans J. Hammers et al.|Journal of Clinical Oncology|2022Cited by 17
Targeting metabolic dysregulation of T cells in kidney cancer.Katy Beckermann, Jeffrey C. Rathmell, Kirsten Young et al.|Journal of Clinical Oncology|2020Cited by 14
TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.Toni K. Choueiri, Robert J. Motzer, Laurence Albigès et al.|Journal of Clinical Oncology|2022Cited by 3
Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.Katy Beckermann, Bradley A. McGregor, Toni K. Choueiri et al.|Journal of Clinical Oncology|2025Cited by 0
Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).Bradley A. McGregor, Robert J. Motzer, Toni K. Choueiri et al.|Journal of Clinical Oncology|2025Cited by 0